Therapy for osteosarcoma: Where do we go from here?

Pediatric Drugs

Volumn 10, Issue 5, 2008, Pages 315-327

  Chou, Alexander J ^a   Geller, David S ^b   Gorlick, Richard ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

Author keywords

Adolescents; Cediranib, therapeutic use; Children; Cisplatin, therapeutic use; Deforolimus, therapeutic use; Doxorubicin, therapeutic use; Etoposide, therapeutic use; Granulocyte macrophage colony stimulating factors, therapeutic use

Indexed keywords

AP 23573; BLEOMYCIN; CEDIRANIB; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; IMC A12; METHOTREXATE; MONOCLONAL ANTIBODY; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; PAMIDRONIC ACID; PEGINTERFERON ALPHA2B; PEMETREXED; R 1507; RAPAMYCIN; RAZOXANE; SCH 717454; TEMSIROLIMUS; TRASTUZUMAB; VINCRISTINE; ZOLEDRONIC ACID;

CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIAGNOSTIC IMAGING; DISEASE FREE SURVIVAL; DRUG MEGADOSE; HUMAN; MAINTENANCE THERAPY; METASTASIS; MONOTHERAPY; OSTEOSARCOMA; OVERALL SURVIVAL; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RECURRENT CANCER; REVIEW;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CHILD; DRUG RESISTANCE, NEOPLASM; HUMANS; OSTEOSARCOMA; SURVIVAL RATE;

EID: 50649107280     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200810050-00005     Document Type: Review

References (143)

1. Jurassic Docs [online]. Available from URL: http://www.ivanhoe.com/ science/story/2006/06/151a.html; 2006 [Accessed 2008 Jul 7]
2. Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 1999 Jul 29; 341 (5): 342-52
3. Chou AJ, Merola PR, Wexler LH, et al. Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience. Cancer 2005 Nov 15; 104 (10): 2214-21
4. Ferrari S, Briccoli A, Mercuri M, et al. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol 2003 Feb 15; 21 (4): 710-5
5. Hawkins DS, Arndt CA. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer 2003 Dec 1; 98 (11): 2447-56
6. Marina N, Gebhardt M, Teot L, et al. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004; 9 (4): 422-41
7. Meyers PA, Gorlick R. Osteosarcoma. Pediatr Clin North Am 1997 Aug; 44 (4): 973-89
8. Hickson ID. RecQ helicases: caretakers of the genome. Nat Rev Cancer 2003 Mar; 3 (3): 169-78
9. Hauben EI, Weeden S, Pringle J, et al. Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. Eur J Cancer 2002 Jun; 38 (9): 1218-25
10. Nakajima H, Sim FH, Bond JR, et al. Small cell osteosarcoma of bone: review of 72 cases. Cancer 1997 Jun 1; 79 (11): 2095-106
11. Bertoni F, Present D, Bacchini P, et al. The Istituto Rizzoli experience with small cell osteosarcoma. Cancer 1989 Dec 15; 64 (12): 2591-9
12. Gibbs CP, Kukekov VG, Reith JD, et al. Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia 2005 Nov; 7 (11): 967-76
13. Tolar J, Nauta AJ, Osborn MJ, et al. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 2007 Feb; 25 (2): 371-9
14. Ifergan I, Meller I, Issakov J, et al. Reduced folate carrier protein expression in osteosarcoma: implications for the prediction of tumor chemosensitivity. Cancer 2003 Nov 1; 98 (9): 1958-66
15. Zhou H, Randall RL, Brothman AR, et al. Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. J Pediatr Hematol Oncol 2003 Jan; 25 (1): 27-32
16. Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors. Cancer Genet Cytogenet 2003 Aug; 145 (1): 1-30
17. Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 2004 Oct; 4 (10): 793-805
18. Classon M, Harlow E. The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer 2002 Dec; 2 (12): 910-7
19. Benassi MS, Molendini L, Gamberi G, et al. Alteration of pRb/p16/cdk4 regulation in human osteosarcoma. Int J Cancer 1999 Oct 22; 84 (5): 489-93
20. David JP, Mehic D, Bakiri L, et al. Essential role of RSK2 in c-Fos-dependent osteosarcoma development. J Clin Invest 2005 Mar; 115 (3): 664-72
21. Nielsen GP, Burns KL, Rosenberg AE, et al. CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations. Am J Pathol 1998 Jul; 153 (1): 159-63
22. Wei G, Lonardo F, Ueda T, et al. CDK4 gene amplification in osteosarcoma: reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons. Int J Cancer 1999 Jan 18; 80 (2): 199-204
23. O'Keefe RJ, Guise TA. Molecular mechanisms of bone metastasis and therapeutic implications. Clin Orthop Relat Res 2003 Oct; 415 Suppl.: S100-4
24. Yang R, Hoang BH, Kubo T, et al. Over-expression of parathyroid hormone Type 1 receptor confers an aggressive phenotype in osteosarcoma. Int J Cancer 2007 Sep; 121 (5): 943-54
25. Link MP, Gebhardt MC, Meyers PA. Osteosarcoma. 4th ed. Philadelphia (PA): Lippincott Williams and Wilkins, 2002
26. Enneking WF. A system of staging musculoskeletal neoplasms. Clin Orthop Relat Res 1986 Mar; 204: 9-24
27. Enneking WF. Musculoskeletal tumor staging: 1988 update. Cancer Treat Res 1989; 44: 39-49
28. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res 1980 Nov-Dec; 153:106-20
29. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol 1994 Feb; 12 (2): 423-31
30. Eilber FR, Rosen G. Adjuvant chemotherapy for osteosarcoma. Semin Oncol 1989 Aug; 16 (4): 312-22
31. Gorlick R, Meyers PA. Osteosarcoma necrosis following chemotherapy: innate biology versus treatment-specific. J Pediatr Hematol Oncol 2003 Nov; 25 (11): 840-1
32. van der Woude HJ, Bloem JL, Hogendoorn PC. Preoperative evaluation and monitoring chemotherapy in patients with high-grade osteogenic and Ewing's sarcoma: review of current imaging modalities. Skeletal Radiol 1998 Feb; 27 (2): 57-71
33. Brenner W, Bohuslavizki KH, Eary JF. PET imaging of osteosarcoma. J Nucl Med 2003 Jun; 44 (6): 930-42
34. Hawkins DS, Rajendran JG, Conrad 3rd EU, et al. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography. Cancer 2002 Jun 15; 94 (12): 3277-84
35. Hawkins DS, Schuetze SM, Butrynski JE, et al. [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol 2005 Dec 1; 23 (34): 8828-34
36. Rougraff BT, Simon MA, Kneisl JS, et al. Limb salvage compared with amputation for osteosarcoma of the distal end of the femur: a long-term oncological, functional, and quality-of-life study. J Bone Joint Surg Am 1994 May; 76 (5): 649-56
37. Mankin HJ, Lange TA, Spanier SS. The hazards of biopsy in patients with malignant primary bone and soft-tissue tumors. J Bone Joint Surg Am 1982 Oct; 64 (8): 1121-7
38. Mankin HJ, Mankin CJ, Simon MA. The hazards of the biopsy, revisited. Members of the Musculoskeletal Tumor Society. J Bone Joint Surg Am 1996 May; 78 (5): 656-63
39. Eckardt JJ, Kabo JM, Kelley CM, et al. Expandable endoprosthesis reconstruction in skeletally immature patients with tumors. Clin Orthop Relat Res 2000 Apr; 373: 51-61
40. Hanlon M, Krajbich JI. Rotationplasty in skeletally immature patients: long-term followup results. Clin Orthop Relat Res 1999 Jan; 358: 75-82
41. Winkelmann WW. Type-B-IIIa hip rotationplasty: an alternative operation for the treatment of malignant tumors of the femur in early childhood. J Bone Joint Surg Am 2000 Jun; 82 (6): 814-28
42. Merkel KD, Gebhardt M, Springfield DS. Rotationplasty as a reconstructive operation after tumor resection. Clin Orthop Relat Res 1991 Sep; 270: 231-6
43. Winkelmann WW. Rotationplasty. Orthop Clin North Am 1996 Jul; 27 (3): 503-23
44. Ruggieri P, De Cristofaro R, Picci P, et al. Complications and surgical indications in 144 cases of nonmetastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy. Clin Orthop Relat Res 1993 Oct; 295: 226-38
45. Kempf-Bielack B, Bielack SS, Jurgens H, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 2005 Jan 20; 23 (3): 559-68
46. Kayton ML, Huvos AG, Casher J, et al. Computed tomographic scan of the chest underestimates the number of metastatic lesions in osteosarcoma. J Ped Surg 2006 Jan; 41 (1): 200-6
47. Pratt CB, Meyer WH, Howlett N, et al. Phase II study of 5-fluorouracil/leucovorin for pediatric patients with malignant solid tumors. Cancer 1994 Nov 1; 74 (9): 2593-8
48. Link MP, Eilber F. Osteosarcoma. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. 1st ed. Philadelphia (PA): JB Lippincott, 1989: 689-711
49. Chello PL, Sirotnak FM, Dorick DM, et al. Cancer schedule-dependent synergism of methotrexate and vincristine against murine L1210 leukemia. Treat Rep 1979; 63 (11-12): 1889-94
50. Jaffe N, Robertson R, Ayala A, et al. Comparison of intra-arterial cis-diamminedichloroplatinum II with high-dose methotrexate and citrovorum factor rescue in the treatment of primary osteosarcoma. J Clin Oncol 1985; 3 (8): 1101-4
51. Bacci G, Avella M, Capanna R, et al. Neoadjuvant chemotherapy in the treatment of osteosarcoma of the extremities: preliminary results in 131 cases treated preoperatively with methotrexate and cisdiamminoplatinum. Ital J Orthop Traumatol 1988; 14 (1): 23-39
52. Grem JL, King SA, Wittes RE, et al. The role of methotrexate in osteosarcoma. J Natl Cancer Inst 1988 Jul 6; 80 (9): 626-55
53. Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986 Jun 19; 314 (25): 1600-6
54. Plowman PN. Bulk disease as the major problem in the cure of paediatric sarcomas. Prog Pediatr Surg 1989; 22: 45-63
55. Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982 Mar 15; 49 (6): 1221-30
56. Rosen G, Marcove RC, Caparros B, et al. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer 1979 Jun; 43 (6): 2163-77
57. Carli M, Passone E, Perilongo G, et al. Ifosfamide in pediatric solid tumors. Oncology 2003; 65 Suppl. 2: 99-104
58. Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005; 23 (9): 2004-11
59. Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol 2000 Dec 15; 18 (24): 4016-27
60. Fuchs N, Bielack SS, Epler D, et al. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 1998 Aug; 9 (8): 893-9
61. Schwartz C, Wexler L, Devidas M, et al. Non-metastatic osteosarcoma: response based augmentation of therapy [abstract no. 666]. Proceedings of the Connective Tissue Oncology Society 12th Annual Meeting; 2006 Nov 2-4; Venice, 11
62. The European and American Osteosarcoma Study Group. EURAMOS I [online]. Available from URL: http://www.ctu.mrc.ac.uk/euramos/e_i_objectives.asp [Accessed 2008 Jun 12]
63. Hristov B, Shokek O, Frassica DA. The role of radiation treatment in the contemporary management of bone tumors. J Natl Compr Canc Netw 2007 Apr; 5 (4): 456-66
64. DeLaney TF, Trofimov AV, Engelsman M, Suit HD. Advanced-technology radiation therapy in the management of bone and soft tissue sarcomas. Cancer Control 2005 Jan-Feb; 12 (1): 27-35
65. Merimsky O, Kollender Y, Inbar M, et al. Palliative treatment for advanced or metastatic osteosarcoma. Isr Med Assoc J 2004 Jan; 6 (1): 34-8
66. Nagarajan R, Clohisy D, Weigel B. New paradigms for therapy for osteosarcoma. Curr Oncol Rep 2005 Nov; 7 (6): 410-4
67. Ozaki T, Flege S, Kevric M, et al. Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol 2003 Jan 15; 21 (2): 334-41
68. DeLaney TF, Park L, Goldberg SI, et al. Radiotherapy for local control of osteosarcoma. Int J Radiat Oncol Biol Phys 2005 Feb 1; 61 (2): 492-8
69. Anderson PM, Wiseman GA, Dispenzieri A, et al. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol 2002 Jan 1; 20 (1): 189-96
70. Saeter G, Hoie J, Stenwig AE, et al. Systemic relapse of patients with osteogenic sarcoma: prognostic factors for long term survival. Cancer 1995 Mar 1; 75 (5): 1084-93
71. Kruh GD, Zeng H, Rea PA, et al. MRP subfamily transporters and resistance to anticancer agents. J Bioenerg Biomembr 2001 Dec; 33 (6): 493-501
72. Nathan SS, Gorlick R, Bukata S, et al. Treatment algorithm for locally recurrent osteosarcoma based on local disease-free interval and the presence of lung metastasis. Cancer 2006 Oct 1; 107 (7): 1607-16
73. Rodriguez-Galindo C, Shah N, McCarville MB, et al. Outcome after local recurrence of osteosarcoma: the St Jude Children's Research Hospital experience (1970-2000). Cancer 2004 May 1; 100 (9): 1928-35
74. Bacci G, Ferrari S, Mercuri M, et al. Predictive factors for local recurrence in osteosarcoma: 540 patients with extremity tumors followed for minimum 2.5 years after neoadjuvant chemotherapy. Acta Orthop Scand 1998 Jun; 69 (3): 230-6
75. Brosjo O. Surgical procedure and local recurrence in 223 patients treated 1982-1997 according to two osteosarcoma chemotherapy protocols: the Scandinavian Sarcoma Group experience. Acta Orthop Scand 1999 Jun; 285 Suppl.: 58-61
76. Weeden S, Grimer RJ, Cannon SR, et al. The effect of local recurrence on survival in resected osteosarcoma. Eur J Cancer 2001 Jan; 37 (1): 39-46
77. Bagatell R, Gore L, Egorin MJ, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clin Cancer Res 2007 Mar 15; 13 (6): 1783-8
78. Khanna C, Prehn J, Hayden D, et al. A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: evaluation of insulin-like growth factor suppression and chemotherapy. Clin Cancer Res 2002 Jul; 8 (7): 2406-12
79. Mansky PJ, Liewehr DJ, Steinberg SM, Chrousos GP, Avila NA, Long L, et al. Treatment of metastatic osteosarcoma with the somatostatin analog OncoLar: significant reduction of insulin-like growth factor-1 serum levels. J Pediatr Hematol Oncol 2002 Aug-Sep; 24 (6): 440-6
80. Laverdiere C, Kolb EA, Supko JG, et al. Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer 2003 Aug 15; 98 (4): 832-40
81. Kleinerman ES. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide. Hematol Oncol Clin North Am 1995 Aug; 9 (4): 927-38
82. Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther 2006 Jul; 6 (7): 1075-85
83. Yang R, Kolb EA, Qin J, et al. The folate receptor alpha is frequently overexpressed in osteosarcoma samples and plays a role in the uptake of the physiologic substrate 5-methyltetrahydrofolate. Clin Cancer Res 2007 May 1; 13 (9): 2557-67
84. Banerjee D, Ercikan-Abali E, Waltham M, et al. Molecular mechanisms of resistance to antifolates: a review. Acta Biochim Pol 1995; 42 (4): 457-64
85. Guo W, Healey JH, Meyers PA, et al. Mechanisms of methotrexate resistance in osteosarcoma. Clin Cancer Res 1999 Mar; 5 (3): 621-7
86. Yang R, Sowers R, Mazza B, et al. Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples. Clin Cancer Res 2003 Feb; 9 (2): 837-44
87. McGuire JJ. Anticancer antifolates: current status and future directions. Curr Pharm Des 2003; 9 (31): 2593-613
88. Purcell WT, Ettinger DS. Novel antifolate drugs. Curr Oncol Rep 2003 Mar; 5 (2): 114-25
89. Tkaczewski I, Tong WP, Spriggs D, et al. Trimetrexate (TMTX) oral bioavailability and lack of cross resistance with HDMTX in patients with recurrent osteosarcoma (OS) [abstract 1504]. Proceedings of the American Society of Clinical Oncology Annual Meeting; 1996 May 18-21; Philadelphia (PA)
90. Trippett T, Meyers P, Gorlick R, et al. High dose trimetrexate with leucovorin protection in recurrent childhood malignancies: a Phase II trial [abstract 889]. Proceedings of the American Society of Clinical Oncology Annual Meeting; 1999 May 15-19; Atlanta (GA)
91. Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 2007 Feb; 6 (2): 404-17
92. Rollins KD, Lindley C. Pemetrexed: a multitargeted antifolate. Clin Ther 2005 Sep; 27 (9): 1343-82
93. Solomon B, Bunn Jr PA. Clinical activity of pemetrexed: a multitargeted antifolate anticancer agent. Future Oncol 2005 Dec; 1 (6): 733-46
94. Villela LR, Stanford BL, Shah SR. Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy. Pharmacotherapy 2006 May; 26 (5): 641-54
95. Walling J. From methotrexate to pemetrexed and beyond: a review of the pharmacodynamic and clinical properties of antifolates. Invest New Drugs 2006 Jan; 24 (1): 37-77
96. Chidiac T, Budd GT, Pelley R, et al. Phase II trial of liposomal doxorubicin (Doxil) in advanced soft tissue sarcomas. Invest New Drugs 2000 Aug; 18 (3): 253-9
97. Judson I, Radford JA, Harris M, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2001 May; 37 (7): 870-7
98. Muggia FM. Liposomal encapsulated anthracyclines: new therapeutic horizons. Curr Oncol Rep 2001 Mar; 3 (2): 156-62
99. Skubitz KM. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma. Cancer Invest 2003 Apr; 21 (2): 167-76
100. Alberts DS, Muggia FM, Carmichael J, et al. Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Semin Oncol 2004 Dec; 31 (6 Suppl. 13): 53-90
101. Chou AJ, Bell MD, Mackinson C, et al. Phase Ib/IIa study of sustained release lipid inhalation targeting cisplatin by inhalation in the treatment of patients with relapsed/progressive osteosarcoma metastatic to the lung [abstract no. 9525]. Proceedings of the American Society of Clinical Oncology (ASCO) 43rd Annual Meeting; 2007 Jun 1-5; Chicago (IL). J Clin Oncol 2007; 25: 18S
102. Rao RD, Markovic SN, Anderson PM. Aerosol therapy for malignancy involving the lungs. Curr Cancer Drug Targets 2003 Aug; 3 (4): 239-50
103. Anderson PM, Markovic SN, Sloan JA, et al. Aerosol granulocyte macrophage colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases. Clin Cancer Res 1999 Sep; 5 (9): 2316-23
104. Anderson PM, Pearson M. Novel therapeutic approaches in pediatric and young adult sarcomas. Curr Oncol Rep 2006 Jul; 8 (4): 310-5
105. Khanna C, Anderson PM, Hasz DE, et al. Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases. Cancer 1997 Apr 1; 79 (7): 1409-21
106. Skubitz KM, Anderson PM. Inhalational interleukin-2 liposomes for pulmonary metastases: a phase I clinical trial. Anticancer Drugs 2000 Aug; 11 (7): 555-63
107. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004 May; 4 (5): 335-48
108. Easton JB, Houghton PJ. mTOR and cancer therapy. Oncogene 2006 Oct 16; 25 (48): 6436-46
109. Vilella-Bach M, Nuzzi P, Fang Y, et al. The FKBP12-rapamycin-binding domain is required for FKBP12-rapamycin-associated protein kinase activity and G1 progression. J Biol Chem 1999 Feb 12; 274 (7): 4266-72
110. Wan X, Mendoza A, Khanna C, et al. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res 2005 Mar 15; 65 (6): 2406-11
111. Casas-Ganem J, Healey JH. Advances that are changing the diagnosis and treatment of malignant bone tumors. Curr Opin Rheumatol 2005 Jan; 17 (1): 79-85
112. McGary EC, Weber K, Mills L, et al. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res 2002 Nov; 8 (11): 3584-91
113. Scotlandi K, Manara MC, Nicoletti G, et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 2005 May 1; 65 (9): 3868-76
114. Pollak MN, Polychronakos C, Richard M. Insulinlike growth factor I: a potent mitogen for human osteogenic sarcoma. J Natl Cancer Inst 1990 Feb 21; 82 (4): 301-5
115. Burrow S, Andrulis IL, Pollak M, et al. Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J Surg Oncol 1998 Sep; 69 (1): 21-7
116. Benini S, Baldini N, Manara MC, et al. Redundancy of autocrine loops in human osteosarcoma cells. Int J Cancer 1999 Feb 9; 80 (4): 581-8
117. Chou A, Merola P, Sowers R, et al. Analysis of aberrant signal transduction pathways in osteosarcoma cell lines [abstract no. 4551]. Proceedings of the American Association of Cancer Research 96th Annual Meeting; 2005 Apr 16-20; Anaheim (CA), 46
118. Akatsuka T, Wada T, Kokai Y, et al. ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer 2002 Mar 1; 94 (5): 1397-404
119. Gorlick R, Huvos AG, Heller G, et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 1999 Sep; 17 (9): 2781-8
120. Hughes DP, Thomas DG, Giordano TJ, et al. Essential erbB family phosphorylation in osteosarcoma as a target for CI-1033 inhibition. Pediatr Blood Cancer 2006 May 1; 46 (5): 614-23
121. Morris CD, Gorlick R, Huvos G, et al. Human epidermal growth factor receptor 2 as a prognostic indicator in osteogenic sarcoma. Clin Orthop Relat Res 2001 Jan (382): 59-65
122. Scotlandi K, Manara MC, Hattinger CM, et al. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. Eur J Cancer 2005 Jun; 41 (9): 1349-61
123. Somers GR, Ho M, Zielenska M, et al. HER2 amplification and overexpression is not present in pediatric osteosarcoma: a tissue microarray study. Pediatr Dev Pathol 2005 Sep-Oct; 8 (5): 525-32
124. Charity RM, Foukas AF, Deshmukh NS, et al. Vascular endothelial growth factor expression in osteosarcoma. Clin Orthop Relat Res 2006 Jul; 448: 193-8
125. DuBois S, Demetri G. Markers of angiogenesis and clinical features in patients with sarcoma. Cancer 2007 Mar 1; 109 (5): 813-9
126. Kaya M, Wada T, Akatsuka T, et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 2000 Feb; 6 (2): 572-7
127. Kaya M, Wada T, Kawaguchi S, et al. Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma. Br J Cancer 2002 Mar 18; 86 (6): 864-9
128. Lee YH, Tokunaga T, Oshika Y, et al. Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. Eur J Cancer 1999 Jul; 35 (7): 1089-93
129. Lee J, Hoang B, Chou A, et al. Expression of vascular endothelial growth factor correlates with chemotherapy response in osteosarcoma patients [abstract no. 3489]. Proceedings of the American Association for Cancer Research Annual Meeting 2007 Apr 14-18; Los Angeles (CA)
130. Maris JM, Courtright J, Houghton PJ, et al. Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr Blood Cancer 2008 Mar; 50 (3): 581-7
131. Mintz MB, Sowers R, Brown KM, et al. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res 2005 Mar 1; 65 (5): 1748-54
132. Guise TA, Yin JJ, Mohammad KS. Role of endothelin-1 in osteoblastic bone metastases. Cancer 2003 Feb 1; 97 (3 Suppl.): 779-84
133. Itoh Y, Tamai M, Yokogawa K, et al. Involvement of multidrug resistance-associated protein 2 in in vivo cisplatin resistance of rat hepatoma AH66 cells. Anticancer Res 2002 May-Jun; 22 (3): 1649-53
134. Wuyts W, Van Wesenbeeck L, Morales-Piga A, et al. Evaluation of the role of RANK and OPG genes in Paget's disease of bone. Bone 2001 Jan; 28 (1): 104-7
135. Miyamoto N, Higuchi Y, Mori K, et al. Human osteosarcoma-derived cell lines produce soluble factor(s) that induces differentiation of blood monocytes to osteoclast-like cells. Int Immunopharmacol 2002 Jan; 2 (1): 25-38
136. Wittrant Y, Lamoureux F, Mori K, et al. RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells. Int J Oncol 2006 Jan; 28 (1): 261-9
137. Ashton JA, Farese JP, Milner RJ, et al. Investigation of the effect of pamidronate disodium on the in vitro viability of osteosarcoma cells from dogs. Am J Vet Res 2005 May; 66 (5): 885-91
138. Cheng YY, Huang L, Lee KM, et al. Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines. Pediatr Blood Cancer 2004 May; 42 (5): 410-5
139. Ory B, Heymann MF, Kamijo A, et al. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer 2005 Dec 1; 104 (11): 2522-9
140. Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008 Jan; 50 (1): 37-45
141. Lock R, Carol H. Houghton PJ, et al. Initial testing (stage 1) of the BH3 memetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer 2008 Jun; 50 (6): 1181-0
142. Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 2008 Apr; 50 (4): 799-805
143. Maris JM, Courtright J, Houghton PJ, et al. Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008 Jul; 51 (1): 42-8